




International
Pharmaceutical
Students' Federation


How Pharmacists Combat Antimicrobial Resistance: Optimising Practices and Raising Awareness



Dr Rasha Abdelsalam Elshenawy

Antimicrobial Resistance Consultant, South Centre, Geneva, Switzerland

Objectives



Identify

how pharmacists contribute to combating antimicrobial resistance in healthcare and public health settings.

Explore

pharmacists' roles as leaders in antimicrobial stewardship programmes and their impact on optimising antimicrobial use.

Learn

effective approaches to involve patients in AMR prevention through education, counselling, and optimised antimicrobial prescribing.

Examine


real-world examples of effective AMS practices to identify strategies that can be applied in different settings.

Understand

how pharmacists can raise awareness and advocate for responsible antimicrobial use to combat AMR globally.

Conflict of Interest

- I have no conflict of interest.



Understanding Antimicrobial Resistance

- **Antimicrobial resistance (AMR)** is a rapidly escalating global health challenge that will cause 39 million deaths between 2025 and 2050.
- It is a global health threat that could kill one person every three seconds by 2050 if no action is taken.
- **Role of Pharmacists:** Pharmacists are central to minimising AMR, especially through AMS efforts, patient education, and optimising antibiotic use.



The Importance of Antimicrobial Stewardship (AMS)

- **AMS Objective:** Minimising resistance by ensuring antibiotics are prescribed only when clinically indicated.
- **AMS Frameworks:** UK's "Start Smart, Then Focus" toolkit, the AMS competency framework, and other best practices.
- **Pharmacists' Role:** Supporting and enforcing AMS principles across healthcare settings.



Sustainability in Antimicrobial Stewardship

- **Antimicrobial stewardship** is crucial for protecting public and global health by ensuring the responsible use of antimicrobials to combat AMR.
- **Sustainability** is key in addressing AMR, as it ensures the long-term effectiveness of antibiotics while reducing environmental impact.



By: Rasha Abdelsalam Elshenawy, UH 2020

The Role of Pharmacists



in Antimicrobial Resistance

Public Health

Promote awareness of antimicrobial resistance

1

Patient Education

Educate patients on responsible antibiotic use.

2

Collaborative Care

Work with healthcare teams to optimize prescribing practices.

3

Vaccination Promotion

Advocate for vaccinations to prevent infections.

4

Community Outreach

Conduct initiatives to raise awareness of AMR.

5


AMS Practice

Actively engage in antimicrobial stewardship programs.

6

UKHSA Antimicrobial Stewardship Clinical Management Algorithm

Start Smart, Then Focus



Pharmacists as Leaders in Antimicrobial Stewardship



- **Collaborative Role:** Pharmacists work closely with prescribers to ensure antibiotics are chosen based on culture and sensitivity results.
- **Streamlining Protocols:** They help develop protocols for empiric therapy, de-escalation, and IV-to-oral switch.
- **Case Study:** Highlight a successful AMS intervention where pharmacists reduced broad-spectrum antibiotic use by implementing a stricter review process.



By: Rasha Abdelsalam Elshenawy, UH 2020

1. Participating in AMS multidisciplinary team

Pharmacist-Led Training

Pharmacists educate doctors, nurses, & other pharmacists on AMS principles and safe prescribing practices.



Continuous Monitoring

They monitor prescription patterns and provide feedback to ensure guidelines are followed.


Example: Share a pharmacist-led training programme's impact, showing a reduction in inappropriate antibiotic prescriptions.

2. Effective Antimicrobial Reviews



Personalising Reviews: Tailor reviews to individual patients to ensure AMS practices align with clinical needs.

Structure of Reviews:



Outcome Options: CARES – Cease, Amend, Refer, Extend, Switch.

3. Patient-Centred Role in AMR Prevention



Patient Education

- Limit antimicrobial therapy to 5-7 days unless otherwise indicated.
- Document diagnosis, antibiotic choice, and review dates to ensure continuity and prevent misuse.

Public Health Awareness

- During WAAW, pharmacists run campaigns to educate the public about the dangers of antibiotic misuse and overuse.

Digital Tools

- Pharmacists utilise apps and resources to help patients manage their medications accurately.

4. Supporting the One Health Approach



01

One Health: Recognises link between human, animal, & environmental health in fighting AMR.

02

Pharmacist Role: Educate on responsible antibiotic use across human and veterinary sectors.

03

Global Effort: Pharmacists contribute to global AMR surveillance and stewardship.

5. Pharmacist-Led Research and Innovation



Research Contributions	Pharmacists conduct studies on AMR trends and AMS strategies.
Innovative Solutions	Emerging technologies, such as mobile apps, for tracking antibiotic usage.
Example	Showcase a pharmacist-led role that contributed to AMR management improvements.

6. Future Directions in AMS and AMR Combat

Leadership in AMS

Pharmacists are increasingly taking on leadership roles in AMS and AMR policy-making.

Technology Integration

Greater use of data analytics and mobile tools to optimise AMS practices.

Global Collaboration

Pharmacists will play a key role in international AMR strategies and partnerships.

FUTURE



Best practice for effective antibiotic review and antimicrobial stewardship

the PHARMACEUTICAL JOURNAL

Monthly edition News CPD & Learning Research PJ Jobs Log in Subscribe

Home / Learning

Antimicrobial stewardship

20 February 2024

By Rasha Abdelsalam Elshenawy

How pharmacists can contribute to effective antimicrobial reviews

Best practice principles and practical advice for structuring antimicrobial reviews and effective stewardship practices.

Download our app for iOS and Android

Copy link to page Download PDF



SHUTTERSTOCK/THE PHARMACEUTICAL JOURNAL

After reading this article, you should be able to:

ADVERTISEMENT

Created and funded by Novartis Pharmaceuticals UK Ltd. Prescribing Information

LEQVIOTM

QOF 2024/2025 LDL-C target for ASCVD patients NOW 2.0mmol/L^{3,4,5}

Learn more

Adverse event reporting, safety information, indication and references.

Adverse event reporting: Adverse events should be reported to Reporting forms and information can be found at <https://www.mhra.gov.uk/adviceandguidance/howtoapply/submitting-an-adverse-event-report>. Adverse events should also be reported to Novartis via medwatch@novartis.com or online at <https://www.novartis.com/medwatch>. Please see all entry country information. If you have a question about the product, please contact Medical Information on 01276 666670 or by email at medinfo@novartis.com.

Safety information: LEQVIO is indicated in adults with primary hypercholesterolaemia. Secondary hypercholesterolaemia, as an adjunct to diet, in combination with a statin or alone with other lipid-lowering therapies. In patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.

Elshenawy, R.A. (2024). How pharmacists can contribute to effective antimicrobial reviews. [online] The Pharmaceutical Journal. Available at: <https://pharmaceutical-journal.com/article/ld/how-pharmacists-can-contribute-to-effective-antimicrobial-reviews>.



Case Study - Applying 'CARES' in AMS

Case Overview: Discuss a real-world scenario where the 'CARES' approach (Cease, Amend, Refer, Extend, Switch) was applied in AMS.

Outcome: Show how structured reviews can enhance antibiotic use and improve patient outcomes.

Lessons Learned: Key insights from applying AMS principles in practice.


Best practice for effective antibiotic review and antimicrobial stewardship



Principles of Initial Antibiotic Assessment

Initial Assessment:

- Follow the "Start Smart" principle by verifying infection presence through history, clinical signs, lab results, and imaging.
- Differentiate between empirical and pathogen-directed antibiotics based on diagnosis and severity.
- Use tools like **CURB-65** for specific infections (e.g., community-acquired pneumonia) to assess severity.




Best practice for effective antibiotic review and antimicrobial stewardship



Principles of Initial Antibiotic Assessment

Key Considerations:

- Assess allergy status to avoid inappropriate second-line antimicrobials.
- Utilise diagnostic tests (e.g., microscopy, culture, sensitivity) to guide therapy adjustments.
- Review within 48-72 hours using the “Then Focus” approach to tailor treatments and ensure adherence to guidelines.



Best practice for effective antibiotic review and antimicrobial stewardship



Person-Centred Care and Stewardship Outcomes

Person-Centred Care:

- Ensure safe and effective antibiotic use by considering individual needs, including dose adjustments and drug interactions.
- Educate patients on antibiotic side effects, such as fluoroquinolone-induced tendon rupture or aminoglycoside nephrotoxicity.
- Emphasise clear communication and shared decision-making for a better understanding of AMR risks.




Best practice for effective antibiotic review and antimicrobial stewardship



Person-Centred Care and Stewardship Outcomes

Outcomes of Antimicrobial Review (CARES):



Best practice for effective antibiotic review and antimicrobial stewardship



Supporting Effective Antimicrobial Stewardship

Duration and Documentation

- Limit antimicrobial therapy to 5-7 days unless otherwise indicated.
- Document diagnosis, antibiotic choice, & review dates to ensure continuity & prevent misuse.

Interprofessional Collaboration

- Engage healthcare teams in antibiotic decisions and updates based on microbiology and patient progress.
- Monitor antibiotic use patterns to optimize prescribing practices.

Patient Education

- Inform patients about the proper use of antibiotics and implications of AMR.
- Reinforce key messages during reviews and utilize evidence-based resources for patient engagement.

Case Study 1



Elshenawy, R.A. (2024). How pharmacists can contribute to effective antimicrobial reviews. [online] The Pharmaceutical Journal. Available at:
<https://pharmaceutical-journal.com/article/ld/how-pharmacists-can-contribute-to-effective-antimicrobial-reviews>.

Case Study: D.L.



Patient Profile:

- 44-year-old woman.
- Presented to A&E in June with symptoms of cough, lethargy, fever, and chills (4-day duration).
- Active lifestyle: runs 25 miles per week, has no recent travel, and works from home.

Vital Signs:

- Respiratory rate: 32 breaths/min.
- Blood pressure: 124/71 mmHg.
- Heart rate: 98 beats/min.
- Oxygen saturation: 93% on room air.
- Fever: 102.1°F (38.9°C).
- White blood cell count: $19.0 \times 10^9/L$.
- Blood urea nitrogen: 17 mg/dL.

Findings:

- Chest X-ray: consolidation in the left lower lobe.
- Diagnosis: Pneumonia.

Case Study: D.L.

CURB-65 Score Calculation

Question: What is D.L.'s CURB-65 score?

Options:

- A. 1
- B. 2
- C. 3
- D. 4



Case Study: D.L.



CURB-65 Criteria:

1. Confusion: **No** (0 pt).
2. BUN >19 mg/dL: **No** (0 pt).
3. Respiratory Rate >30: **Yes** (1 pt).
4. Blood Pressure <90/60 mmHg: **No** (0 pt).
5. Age ≥65: **No** (0 pt).

Total Score: 1

CURB-65

<u>C</u> onfusion	1
b <u>U</u> n 20+	1
<u>R</u> R 30+	1
<u>B</u> P <90/60	1
Age > <u>65</u>	1
	<hr/>
	5


0-1	Outpatient
2	Inpatient
3+	ICU

Case Study: D.L.

Answer: A

Significance:

- CURB-65 helps assess pneumonia severity and guides hospital admission decisions.
- A score of 1 suggests **low mortality risk**; hospitalisation is appropriate for management.



Case Study: D.L.



Discharge Plan

Question: What is the most appropriate next step for D.L.?

Options:

- A. Discontinue antibiotic therapy
- B. Continue antibiotic therapy for two more days with azithromycin orally
- C. Continue antibiotic therapy for two more days with ceftriaxone orally
- D. Continue antibiotic therapy for two more days with levofloxacin orally

Case Study: D.L.



Discharge Plan Answer: A. Discontinue antibiotic therapy

Rationale: D.L. is clinically stable:

- Afebrile for >72 hours.
- Respiratory rate: 18 breaths/min.
- Blood pressure: 112/70 mmHg.
- Oxygen saturation: 98% on room air.
- WBC: 12×10^3 cells/mm³. notes for the slides!

Case Study: D.L.



Why discontinue?

- No clinical instability or infection concerns.
- Continuing therapy is unnecessary and may cause adverse effects and antimicrobial resistance.

Case Study: D.L.



Incorrect Options: B-D: Additional therapy is unwarranted.

- **Azithromycin:** High *S. pneumoniae* resistance risk.
- **Levofloxacin:** Risk of tendon rupture and other side effects.
- **Ceftriaxone:** Unnecessary broad-spectrum coverage.

This structure ensures clarity, stepwise explanation, and focus on clinical reasoning. Let me know if you'd like any design enhancements or additional notes for the slides!

Case Study 2




Case 2: Treatment of Community-Acquired Pneumonia



- Mr. James, a 55-year-old male, presents with mild community-acquired pneumonia (CAP) at his local GP clinic. The GP prescribes co-amoxiclav.
- However, the likely pathogen, *Streptococcus pneumoniae*, could be treated effectively with amoxicillin (a narrow-spectrum antibiotic), which is the first-line treatment for uncomplicated CAP.
- Mr. James has no known allergies and has not taken antibiotics recently.

Answer the Following Questions:



Q1) What is the first-line treatment for uncomplicated community-acquired pneumonia (CAP) caused by the identified pathogen?



- A) Co-amoxiclav
- B) Amoxicillin
- C) Azithromycin
- D) Ciprofloxacin

NICE
National Institute for
Health and Care Excellence

Q1) What is a potential concern with prescribing co-amoxiclav without sputum cultures?




- A) Increased patient comfort
- B) Risk of antimicrobial resistance
- C) Enhanced effectiveness of treatment
- D) Improved recovery time



Patient Safety Focus

- Using a broad-spectrum antibiotic like co-amoxiclav unnecessarily exposes Mr. James to higher risks of side effects, such as **gastrointestinal issues and Clostridium difficile infection (CDI)**. The first-line treatment for CDI is oral vancomycin.
- Broad-spectrum antibiotic use also contributes to the development of **antimicrobial resistance in both the patient and the community**.



Pharmacist's Role in Antibiotic Selection



1. Pharmacist's Role in Antibiotic Selection:

The pharmacist reviews the prescription and advises switching to **amoxicillin**, a more appropriate narrow-spectrum antibiotic for CAP, which is just as effective in this case and safer for the patient.

Antimicrobial stewardship intervention involves **de-escalation or amend.**



Pharmacist's Role in Antibiotic Selection



2. Assessing Allergies:

The pharmacist should confirm Mr. James's lack of penicillin allergies, which would support the safe use of amoxicillin.

3. Minimising Side Effects:

The pharmacist educates Mr. James about the lower risk of side effects with narrow-spectrum antibiotics like amoxicillin, as compared to co-amoxiclav.



Antimicrobial Stewardship Resources



2. NICE: National Institute for Health and Care Excellence

NICE National Institute for Health and Care Excellence

Search NICE...

Sign in

Guidance

Standards and indicators ▼

Life sciences ▼

British National Formulary (BNF)

British National Formulary for Children (BNFC)


Clinical Knowledge Summaries (CKS)

About ▼

We produce useful and useable guidance for the NHS and wider health and care system.

Our recommendations help practitioners and commissioners get the best care to people, fast, while ensuring value for the taxpayer.

[Find guidance](#)



3. British National Formulary (BNF)

Key information on the selection, prescribing, dispensing and administration of medicines.

Guidance

Standards and indicators

Life sciences

British National Formulary (BNF)

British National Formulary for Children (BNFC)

Clinical Knowledge Summaries (CKS)

About

BNF

Drugs

Interactions

Treatment summaries

What's changed?

About BNF

[NICE](#) > BNF

British National Formulary (BNF)

Key information on the selection, prescribing, dispensing and administration of medicines.

Last updated:
28 August 2024
[See what's changed](#)

Drugs

Drug monographs describe the uses, doses, safety issues, medicinal forms and other considerations involved in the use of a drug.

Treatment summaries

Browse an A to Z list of treatment summaries covering:

- drug use related to a particular body system

4. UK Health Security Agency - GOV.UK

 **GOV.UK**

▼ Menu

Q

[Home](#) > [Organisations](#)


UK Health
Security
Agency

[UKHSA emergency contacts](#)

[Our health protection services](#)

[Contact our regional health protection teams](#)

[UKHSA research](#)

[Careers at UKHSA](#)

[Vaccine Development and Evaluation Centre \(VDEC\)](#)


Featured


news
[ment/news/ready-for-uni-life-use-condoms-to-keep-stis-away](#)


press


blog

5. Royal Pharmaceutical Society | RPS



Antimicrobial Resistance and Stewardship


Committing to tackling antimicrobial resistance (AMR)

This is our main resource for the fight against antimicrobial resistance, and promoting the best use of antimicrobial stewardship.

We're bringing pharmacy expertise and knowledge to the fight, and we need your help.

6. The UK Next Five - Year Action Plan

Confronting Antimicrobial Resistance



Further Recommended Readings



1



The couple was admitted to
the **COVID-19 ICU ward**



The wife was deteriorating due to Multi-Drug
Resistance (MDR) Bacteria. She was lucky,
there was an antibiotic **Reserved** to treat her

2



A tale of two pandemics - **COVID-19**
and **Antimicrobial Resistance (AMR)**



Antimicrobial Stewardship (AMS) maintains
the effective and right use of antibiotics

3



Identify **factors** affecting antibiotics use before and
during the COVID-19 pandemic



Provide **practical ways** to improve safety and quality of patient care

1. 'Start Smart' - 'Then Focus'



COVID

Submit to this Journal

Review for this Journal

Propose a Special Issue

Article Menu

Academic Editor



Martin Thomas Falk

Subscribe SciFeed

Recommended Articles



Order Article Reprints

Open Access

Article

Impact of COVID-19 on 'Start Smart, Then Focus' Antimicrobial Stewardship at One NHS Foundation Trust in England Prior to and during the Pandemic

by **Rasha Abdelsalam Elshenawy** * , **Nkiruka Umaru**  and **Zoe Aslanpour**  

Department of Clinical Pharmacy and Pharmaceutical Sciences, School of Life and Medical Sciences, University of Hertfordshire, Hatfield AL10 9AB, UK

* Author to whom correspondence should be addressed.

COVID **2024**, 4(1), 102-116; <https://doi.org/10.3390/covid4010010>

Submission received: 30 November 2023 / Revised: 16 January 2024 / Accepted: 18 January 2024 / Published: 21 January 2024


Download 

Browse Figures

Versions Notes


Factors Affecting 'Start Smart' Antibiotic Prescribing

- Factors affecting empirical or initial antibiotic prescribing include the following:





Factors Affecting ‘Then Focus’ Antibiotic prescribing

- Factors affecting pathogen-directed antibiotic prescribing include the following:



2. Journal of Global Antimicrobial Resistance

- Examining the pandemic's impact on the **‘Five Rights of Antibiotic Use’** (right patient, drug, dose, time, and duration).
- This could be used in quality improvement projects to maintain the sustainability of AMS implementation and mitigate AMR challenges.



3. The Pharmaceutical Journal

How pharmacists can contribute to effective antimicrobial reviews



the PHARMACEUTICAL JOURNAL

Monthly edition

News

CPD & Learning

Research

PJ Jobs

My account

Home / Learning

Antimicrobial stewardship

20 February 2024



By Rasha Abdelsalam Elshenawy

How pharmacists can contribute to effective antimicrobial reviews

Best practice principles and practical advice for structuring antimicrobial reviews and effective stewardship practices.

Copy link to page

Download PDF

Add bookmark



Elshenawy, R.A. (2024). How pharmacists can contribute to effective antimicrobial reviews. [online] The Pharmaceutical Journal. Available at: <http://pharmaceutical-journal.com/article/ld/how-pharmacists-can-contribute-to-effective-antimicrobial-reviews>.

4. AWaRe Classification of Antimicrobials

- The AWaRe classification of antibiotics as a tool to support antibiotic stewardship efforts at local, national and global levels.
- Antibiotics are classified into three groups, **Access**, **Watch** and **Reserve**, to emphasise the importance of their appropriate use.

Access Group

This group includes antibiotics and antibiotic classes that have activity against a wide range of commonly encountered susceptible pathogens while showing lower resistance potential than antibiotics should be widely available, affordable, and quality-assured to improve access and promote appropriate use. Selected Access group antibiotics (shown here) are included on the WHO as essential first-choice or second-choice empirical treatment options for specific infectious syndromes.

Amikacin	Cefazolin	Nitrofurantoin
Amoxicillin	Chloramphenicol	Phenoxy methylpenicillin
Amoxicillin. Clavulanic acid	Clindamycin	Procaine benzylpenicillin
Ampicillin	Cloxacillin	Spectinomycin
Benzathine benzylpenicillin	Doxycycline	Sulfamethoxazole. trimethoprim
Benzylpenicillin	Gentamicin	
Cefalexin	Metronidazole	

Watch Group

This group includes antibiotics and antibiotic classes with higher resistance potential. It has most of the highest priority agents among the critically important antimicrobials (CIA) for human medicine and/or antibiotics that are at relatively high risk of selection of bacterial resistance. Watch group antibiotics should be prioritised as key national and local stewardship programmes and monitoring targets. Selected watch group antibiotics (shown here) are included in the WHO as essential first-choice or second-choice empirical treatment options for a limited number of specific infectious syndromes.

Azithromycin	Ciprofloxacin
Cefixime	Clarithromycin
Cefotaxime	Meropenem
Ceftazidime	Piperacillin-tazobactam
Ceftriaxone	Vancomycin
Cefuroxime	

Reserve Group

This group includes antibiotics and antibiotic classes that should be reserved for treating confirmed or suspected infections due to multi-drug-resistant organisms and treated as last-resort options. Their use should be tailored to highly specific patients and settings when all alternatives have failed or are not suitable. They could be protected and prioritised as a key target of national and international stewardship programmes involving monitoring and utilisation reporting to preserve their effectiveness. Selected Reserve group antibiotics (shown here) are included on the WHO EML when they have a favourable risk-benefit profile and proven activity against "critical priority" or "high priority" pathogens identified by the WHO priority pathogens List, notably carbapenem-resistant Enterobacteriaceae.

Ceftazidime * avibactam
Colistin
Fosfomycin (intravenous)
Linezolid
Meropenem. vaborbactam
Plazomicin
PolymyxinB

“WHO AWaRe classification for antibiotic stewardship: tackling antimicrobial resistance – a descriptive study from an English NHS Foundation Trust prior to and during the COVID-19 pandemic”

 Check for updates

OPEN ACCESS

EDITED BY
Saurabh Mishra,
Cornell University, United States

REVIEWED BY
Feng Zhou,
Henan Institute of Science and Technology,
China
Biplab Singha,
University of Massachusetts Medical School,
United States

*CORRESPONDENCE
Rasha Abdelsalam Elshenawy
✉ r.a.elshenawy@herts.ac.uk

RECEIVED 22 September 2023
ACCEPTED 20 November 2023
PUBLISHED 11 December 2023

CITATION
Abdelsalam Elshenawy R, Umaru N and
Aslanpour Z (2023) WHO AWaRe classification
for antibiotic stewardship: tackling
antimicrobial resistance – a descriptive study
from an English NHS Foundation Trust prior to
and during the COVID-19 pandemic.
Front. Microbiol. 14:1298858.
doi: 10.3389/fmicb.2023.1298858

COPYRIGHT
© 2023 Abdelsalam Elshenawy, Umaru and
Aslanpour. This is an open-access article
distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The
use, distribution or reproduction in other
forums is permitted, provided the original
author(s) and the copyright owner(s) are
credited and that the original publication in this
journal is cited, in accordance with accepted
academic practice. No use, distribution or
reproduction is permitted which does not
comply with these terms.

WHO AWaRe classification for antibiotic stewardship: tackling antimicrobial resistance – a descriptive study from an English NHS Foundation Trust prior to and during the COVID-19 pandemic

Rasha Abdelsalam Elshenawy*, Nkiruka Umaru and
Zoe Aslanpour


Department of Pharmacy, School of Life and Medical Sciences, University of Hertfordshire, Hatfield,
United Kingdom

Antimicrobial resistance (AMR) is a silent and rapidly escalating pandemic, presenting a critical challenge to global health security. During the pandemic, this study was undertaken at a NHS Foundation Trust in the United Kingdom to explore antibiotic prescribing trends for respiratory tract infections (RTIs), including pneumonia, and the COVID-19 pandemic across the years 2019 and 2020. This study, guided by the WHO's AWaRe classification, sought to understand the impact of the pandemic on antibiotic prescribing and antimicrobial stewardship (AMS). The research methodology involved a retrospective review of medical records from adults aged 25 and older admitted with RTIs, including pneumonia, in 2019 and 2020. The application of the AWaRe classification enabled a structured description of antibiotic use. The study evaluated antibiotic use in 640 patients with RTIs. Notably, it observed a slight increase in the use of amoxicillin/clavulanic acid and a substantial rise in azithromycin prescriptions, highlighting shifts in prescribing trends. Despite these changes, some antibiotics displayed steady consumption rates. These findings highlight the importance of understanding antibiotic use patterns during the AMR threat. The increase in the usage of "Watch" category antibiotics during the pandemic emphasises the urgency of robust AMS measures. The research confirms that incorporating the AWaRe classification in prescribing decisions is crucial for patient safety and combating antibiotic misuse. This study provides essential insights into the changing landscape of antibiotic prescribing during a global health crisis, reinforcing the necessity for ongoing AMS vigilance to effectively address AMR challenges.

KEYWORDS

AWaRe, antibiotic stewardship, COVID-19, NHS, hospitals, antimicrobial resistance


This paper provided a **heatmap** for **antibiotic use** in 2019 and 2020 according to AWaRe criteria and top prescribed antibiotics.



WHO Access, Watch, Reserve (AWaRe) classification for antibiotics evaluation and monitoring before and during the COVID-19 pandemic								
Access	Mar-19	Jun-19	Sep-19	Dec-19	Mar-20	Jun-20	Sep-20	Dec-20
Amoxicillin	2	1	2	3	6	6	0	1
Amoxicillin/clavulanic acid	67	61	56	76	25	70	86	66
Benzylpenicillin	1	0	2	0	3	0	0	0
Doxycycline	1	1	3	2	1	2	0	1
Flucloxacillin	2	2	3	2	0	5	2	1
Gentamicin	0	0	0	0	0	2	0	0
Metronidazole	3	7	2	0	4	4	2	4
Sulfamethoxazole/Trimethoprim	0	1	1	0	4	2	0	0
Clindamycin	1	0	0	0	0	0	0	0
Cephalexin	0	0	2	1	1	0	0	0
Watch	Mar-19	Jun-19	Sep-19	Dec-19	Mar-20	Jun-20	Sep-20	Dec-20
Azithromycin	0	1	2	0	13	19	3	11
Ceftazidime	2	2	0	0	0	1	0	0
Ceftriaxone	0	0	0	1	1	0	1	0
Cefuroxime	0	0	1	0	0	0	0	0
Ciprofloxacin	3	3	1	8	7	5	9	5
Clarithromycin	14	21	26	33	32	21	25	32
Levofloxacin	12	9	8	11	14	13	14	23
Meropenem	2	0	1	1	5	4	4	5
Piperacillin/Tazobactam	29	30	15	16	29	21	22	25
Teicoplanin	0	0	1	0	3	0	0	0
Vancomycin	1	4	0	1	0	1	0	0
Reserve	Mar-19	Jun-19	Sep-19	Dec-19	Mar-20	Jun-20	Sep-20	Dec-20
Aztreonam	0	0	0	0	0	1	0	0
Cefazidime/Azobactam	0	0	2	0	0	0	0	0
Linezolid	3	2	1	1	0	0	1	1

0: Absence of antibiotic usage
1 - 9: Minimal antibiotic consumption
10 - 29: Moderate level of antibiotic usage
30 and above: High level of antibiotic consumption

Summary - Key Takeaways



Central Role in AMS

Open Floor for Questions

Importance of Training
& Resources

Acknowledgement of WAAW

Impact of WAAW



Call to Action




Acknowledgement of WAAW:

Encourage participation in WAAW to amplify education efforts and community engagement.

Importance of Training and Resources:

Continuous education and resource access are vital for effective AMS

Conclusion



Impact of WAAW:

Use this week to promote AMS efforts, public awareness, and cross-sector collaboration.

Open Floor for Questions:

Invite attendees to discuss AMS challenges, solutions, and future directions.

Central Role in AMS:

Pharmacists are essential in combatting AMR through AMS.

Call to Action:

Pharmacists must lead AMS efforts to reduce AMR and ensure responsible antibiotic use and sustainable AMS practices.

References



- Abdelsalam Elshenawy R, Umaru N, Aslanpour Z. Impact of COVID-19 on “Start Smart, Then Focus” Antimicrobial Stewardship at One NHS Foundation Trust in England Prior to and during the Pandemic. COVID [Internet]. 2024 Jan 1;4(1):102–16. Available from: <https://www.mdpi.com/2673-8112/4/1/10>.
- Department of Health and Social Care. UK 5-year action plan for antimicrobial resistance 2024 to 2029 [Internet]. GOV.UK. 2024. Available from: <https://www.gov.uk/government/publications/uk-5-year-action-plan-for-antimicrobial-resistance-2024-to-2029>.
- GBD 2021 Antimicrobial Resistance Collaborators (2024). Global burden of antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050. The Lancet. doi:[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(24\)01867-1/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01867-1/fulltext).
- WHO. The WHO AWaRe (Access, Watch, Reserve) antibiotic book - Infographics [Internet]. www.who.int. 2023. Available from: <https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2022.02>.

THANK YOU!

Dr Rasha Abdelsalam Elshenawy

r.elshenawy@herts.ac.uk

Twitter: Salam_Rasha